181/344US=8 / Dermatologia
Williams IR, Rich B, Kupper TS. Cytokines. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editores. Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill, 2008. p. 285-95. ISBN 978-0-07138076-0.

CITOCINAS; VIAS DE TRANSDUCAO DE SINAL; TNF-ALFA; RECEPTOR HEMATOPOIETINA; FAMILIA DE RECEPTORES DE CITOCINAS

182/344US=84 / Biol/Mol
Liu F. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: component hardware for transformig growth factor-B signal transduction: regulation of smad activity by phosphorylation. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 105-23. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TGF-B; SMAD; FOSFORILACAO; FOSFATASE; QUINASE DO RECEPTOR; MAP QUINASE; CDK; CANCER

183/344US=84 / Biol/Mol
Hayashida T, Gupta V, Thiagalingam S, Maheswaran S. TGF-B superfamily members in normal and tumor biology: activins, inhibins, and bone morphogenetic proteins as modulators and biomarkers of prostate cancer progression. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 355-72. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

CANCER DE PROSTATA; ACTIVINA; PROTEINAS MORFOGENETICAS DO OSSO; INIBINAS; ALK2; ALK3; ALK6; ACTIVINA RECEPTOR TIPO II; BMP RECEPTOR TIPO II

184/344US=84 / Biol/Mol
Berberian G, Malhotra D, Langenfeld JE. TGF-B superfamily members in normal and tumor biology: bone morphogenic proteins and angiogenesis in developing tumors. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 373-81. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

ACTIVINA; PROTEINAS MORFOGENETICAS DO OSSO; INIBINAS; ALK2; ALK3; ALK6; ACTIVINA RECEPTOR TIPO II; BMP RECEPTOR TIPO II

185/344US=84 / Biol/Mol
Mazerbourg S. TGF-B superfamily members in normal and tumor biology: bone morphogenetic proteins/growth differentiation factors and smad activation in ovarian granulosa cells and carcinoma. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 425-50. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TGF-B; BMP; GDF; SMAD; TGF-B RECEPTOR; CANCER NO OVARIO; OVARIO; CELULAS DA GRANULOSA; VIA DE SINALIZACAO

186/344US=84 / Biol/Mol
López-Casillas F, Vilchis-Landeros MM, Esparza-López J, Ponce-Castañeda MV, Velasco-Loyden NG, Juárez P, Montiel JL, Mendoza V. TGF-B superfamily members in normal and tumor biology: regulation of the transforming growth factor-B superfamily by betaglycan. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 451-61. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TGF-B TIPO III RECEPTOR; TGF-B; TGF-B INIBIDORES; TUBERCULOSE; BETAGLICAM; BETAGLICAM NULOS RATOS; ECOTODOMAIN DERRAMAMENTO; DESENVOLVIMENTO CABECA; INIBINA; NEFROPATIAS; XENOGRAFS TUMORAIS

187/344US=84 / Biol/Mol
Suh N. TGF-B in inflammation and fibrosis: triterpenoids, vitamina D, and TGF-B/smad signaling in inflammation and cancer. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 525-47. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TGF-B; SMAD; CANCER; INFLAMATORIO; RECEPTOR NUCLEAR

188/344US=84 / Biol/Mol
Liu W, Chua C, Gao Z, Wu X, Cao Y. TGF-B in inflammation and fibrosis: overexpressed truncated TGF-B type II receptor inhibits fibrotic behavior of keloid fibroblasts in vitro and experimental scar formation in vivo. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 703-21. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

TRUNCATED TGF-B RECEPTOR II; TGF-B SINALIZACAO; FERIR CICATRIZES; QUELOIDE; TERAPIA GENETICA CICATRIZ

189/344US=84-A / Biol/Mol
Ungefroren H. Transformig growth factor-B in developing and advanced cancers: TGF-B signaling and biglycan in pancreatic cancer. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 51-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

CANCER DE PANCREAS; RECEPTOR; SMAD; BIGLICAM; PARAGEM DO CRESCIMENTO; DANO DO DNA-45B; P38 CINASE DE PROTEINA ACTIVADA POR MITOGENIO; NADPH OXIDASE; PROTEINA QUINASE C; FACTOR DE CRESCIMENTO TRANSFORMANTE-B

190/344US=84-A / Biol/Mol
Yasui H, Hideshima T, Anderson KC. Transformig growth factor-B in developing and advanced cancers: inhibition of TGF-B signaling in multiple myeloma and its bone marrow microenvironment. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 219-27. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B; IL-6; VEGF; TGF-B RECEPTOR TIPO I; TBRI; MIELOMA MULTIPLO; MICROAMBIENTE DA MEDULA OSSEA; FATOR TRANSFORMADOR DE CRESCIMENTO; FACTOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDOR DE QUINASE SD-208

191/344US=84-A / Biol/Mol
Song K, Danielpour D. Transformig growth factor-B in developing and advanced cancers: key roles of TGF-B and smad3 in prostate cancer. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 229-46. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

PROSTATA; SMAD3; IGF-I; AKT; MTOR; ARA55/HIC-5; RECEPTOR DE ANDROGENO

192/344US=84-A / Biol/Mol
Ruscetti F, Akel S, Birchenall-Roberts M, Cao Z, Roberts AB. Transformig growth factor-B in developing and advanced cancers: smad signaling in leukemic growth and differentiation: crosstalk between smad and multiple pathways through activation of the TGF-B type I receptor. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 247-61. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

FATOR TRANSFORMADOR DE CRESCIMENTO - B; LEUCEMIA; DIFERENCIACAO; CROSSTALK SMAD SINALIZACAO; MAPK SINALIZACAO TUBERINA

193/344US=84-A / Biol/Mol
Ammanamanchi S, Brattain MG. Transformig growth factor-B in developing and advanced cancers: DNA methylation and histone deacetylation inhibitors as potential therapeutic agents for the reconstitution of TGF-B signaling in breast cancer. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 463-74. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

METILACAO DO DNA; DECITABINA; DESACETILACAO DAS HISTONAS; RII; TGF-B RECEPTOR TIPO II; SP FAMILIA DE GENES; TRICOSTATINA A

194/344US=84-A / Biol/Mol
Reiss M. Development of inhibitors of transforming growth factor-B signaling for therapy: targetin transforming growth factor-B in metastasis: in vitro and in vivo mechanisms. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 609-34. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

FATOR TRANSFORMADOR DE CRESCIMENTO - B; ANGIOGENESE; CANCER; MOTILIDADE; RESPOSTA IMUNE; INVASAO; METASTASE; TGF-B DO TIPO I; INIBIDOR DA QUINASE DO RECEPTOR; CRESCIMENTO TUMORAL

195/344US=84-A / Biol/Mol
Naumann U, Weller M. Development of inhibitors of transforming growth factor-B signaling for therapy: modulating TGF-B receptor signaling: a novel approach of cancer therapy. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 653-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B; TGF-B RECEPTORES; MOLECULAS PEQUENAS; DOMINANTE NEGATIVO; RECEPTOR SOLUVEL

196/344US=84-A / Biol/Mol
De Crescenzo G, Chao H, Zwaagstra J, Durocher Y, O'Connor-McCourt MD. Development of inhibitors of transforming growth factor-B signaling for therapy: engineering TGB-B traps: artificially dimerized receptor ectodomains as high-affinity blockers of TGF-B action. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 671-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

FACTOR DE CRESCIMENTO TRANSFORMANTE-B; ANTAGONISTA; BETAGLICAM; ARMADILHA LIGANTE; RECEPTOR ECTODOMINIO

197/344US=84-A / Biol/Mol
Ling LE, Singh J, Chuaqui CE, Boriack-Sjodin PA, Corbley MJ, Lepage DJ, Silverio EL, Sun L, Papadatos JL, Shan F, Pontz T, Kam Cheung H, Zhang X, Arduini RM, Mead JN, Newman MN, Bowes S, Josiah S, Lee WC. Development of inhibitors of transforming growth factor-B signaling for therapy: the use of virtual screening in ALK5 kinase inhibitor discovery and validation of orally active ALK5 kinase inhibitors in oncology. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 685-96. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

VIRTUAL; FARMACOFORO; INIBIDOR DE CINASE; ALK5; TGF-B RECEPTOR TIPO I; CRISTALOGRAFIA DE RAIOS X; TGF-B

198/344US=84-A / Biol/Mol
Suzuki E, Albelda SM. Development of inhibitors of transforming growth factor-B signaling for therapy: soluble type II transforming growth factor-B receptor inhibits tumorigenesis by augmenting host ntitumor immunity. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 697-706. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B; IMUNIDADE ANTITUMORAL; MESOTELIOMA MALIGNO; SOLUVEL DO TIPO II DO RECEPTOR DE TGF-B

199/344US=84-A / Biol/Mol
Lacher MD, Korn WM, Akhurst RJ. Development of inhibitors of transforming growth factor-B signaling for therapy: reversal of EMT by small-molecule inibitors of TGF-B type I and II receptors: implications for carcinoma treatment. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 707-22. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B RECEPTORES; PEQUENAS MOLECULAS INIBIDORES; EPITELIAL PARA MESEACHYMAL TRANSICAO; EMT; METASTASE; VIRUS COXSACKIE E RECEPTOR ADENOVIRUS; TERAPIA DO CANCRO ADENOVIRAL

200/344US=84-A / Biol/Mol
Bandyópadhyay A, Sun L. Development of inhibitors of transforming growth factor-B signaling for therapy: soluble TGF-B type III receptor suppresses malignant progression of human cancer cells. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 723-35. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

ANGIOGENESE; METALOPROTEINASE DE MATRIZ-9; METASTASE PULMONAR; METASTASE OSSEA; BETAGLICAM SOLUVEL; TGF-B; TGF-B TIPO DE INIBIDORES DO RECEPTOR III; TUMORIGENESE

Primeira | Anterior | Próxima | Última